Trial Profile
A phase III trial of APTIOM (eslicarbazepine acetate) for Partial epilepsies in children younger than four years of age.
Status:
Planning
Phase of Trial:
Phase III
Latest Information Update: 01 Feb 2024
Price :
$35
*
At a glance
- Drugs Eslicarbazepine acetate (Primary)
- Indications Partial epilepsies
- Focus Therapeutic Use
- 03 Apr 2023 According to a Sumitomo Pharma media release, the Sumitomo Pharma USA companies (Sumitovant Biopharma, Myovant Sciences, Urovant Sciences, Enzyvant Therapeutics, Sumitomo Pharma America Holdings, Sumitomo Pharma Oncology and Sunovion Pharmaceuticals) combined and named as Sumitomo Pharma America
- 15 Mar 2017 New trial record